dna
array
highthroughput
sequenc
viru
identif
porcin
reproduct
respiratori
syndrom
viru
prrsv
propidium
monoazid
pma
ethidium
bromid
monoazid
ema
b
r
c
panvir
dna
array
pvda
highthroughput
sequenc
ht
use
tool
identifi
novel
virus
emerg
diseas
howev
techniqu
difficulti
identifi
virus
clinic
sampl
host
genom
nucleic
acid
content
hgcont
propidium
monoazid
pma
ethidium
bromid
monoazid
ema
capac
bind
free
dnarna
cell
membraneimperm
thu
unabl
bind
protect
nucleic
acid
viral
genom
within
intact
virion
howev
emapma
modifi
genet
materi
amplifi
enzym
order
assess
potenti
emapma
lower
presenc
amplifi
hgcont
sampl
improv
viru
detect
serum
lung
tissu
homogen
spike
porcin
reproduct
respiratori
viru
prrsv
process
emapma
addit
prrsv
rtqpcr
posit
clinic
sampl
also
test
emapma
treatment
significantli
decreas
amplifi
hgcont
significantli
increas
number
pvda
posit
probe
signal
intens
compar
untreat
spike
lung
sampl
emapma
treatment
also
increas
sensit
ht
increas
number
specif
prrsv
read
prrsv
percentag
coverag
interestingli
emapma
treatment
significantli
increas
sensit
pvda
ht
two
three
clinic
tissu
sampl
thu
emapma
treatment
offer
new
approach
lower
amplifi
hgcont
clinic
sampl
increas
success
pvda
ht
identifi
virus
emerg
new
viral
diseas
repres
constant
threat
human
anim
health
fortun
past
decad
access
novel
technolog
improv
detect
identif
unknown
virus
clinic
sampl
novel
viru
identif
process
base
viral
genom
detect
use
new
technolog
like
panvir
dna
microarray
pvda
highthroughput
sequenc
ht
first
pvda
contain
oligonucleotid
probe
target
highli
conserv
dna
sequenc
distinct
select
viral
genom
report
wang
et
al
sinc
pvda
develop
includ
latest
version
oligonucleotid
probe
target
approxim
distinct
viral
genom
chen
et
al
technolog
use
rapidli
identifi
virus
involv
human
ill
like
sever
acut
respiratori
syndrom
sar
wang
et
al
anim
diseas
chen
et
al
use
technolog
interest
result
gener
obtain
within
day
requir
advanc
technolog
result
interpret
chen
et
al
howev
pvda
depend
select
probe
contain
toler
nucleotid
mismatch
dna
hybrid
process
requir
detect
identif
virus
clinic
sampl
delwart
decreas
cost
made
ht
technolog
access
consequ
use
identifi
novel
unknown
virus
affect
human
anim
plant
increas
massart
et
al
lipkin
firth
quinonesmateu
et
al
even
led
discoveri
unforeseen
virus
clinic
sampl
bellehumeur
et
al
metagenom
sequenc
potenti
determin
entireti
nucleic
acid
sequenc
within
sampl
includ
viral
nucleic
sequenc
interest
hall
et
al
metagenom
dna
sequenc
obtain
ht
compar
genom
databas
order
identifi
nucleic
acid
sequenc
associ
known
virus
one
major
benefit
metagenom
sequenc
clinic
sampl
potenti
detect
assembl
genom
novel
virus
barzon
et
al
although
pvda
ht
led
discoveri
new
virus
last
year
especi
isol
virus
techniqu
neg
impact
presenc
nucleic
acid
found
clinic
sampl
mainli
host
genom
dnarna
kang
et
al
high
host
viral
dna
ratio
extract
clinic
sampl
greatli
decreas
pvda
sensit
sinc
amplifi
label
dna
correspond
host
dna
kang
et
al
sequenc
depend
method
tissu
prepar
viral
particl
concentr
high
host
viral
dna
ratio
decreas
sensit
technolog
yang
et
al
read
must
obtain
order
detect
presenc
viru
clinic
sampl
increas
sequenc
cost
lower
throughput
creat
potenti
bioinformat
bottleneck
thu
order
improv
viral
detect
clinic
sampl
ht
pvda
level
host
genom
dna
must
lower
gener
done
treat
sampl
combin
ultracentrifug
filtrat
andor
nucleas
treatment
typic
dnase
andor
rnase
treatment
hall
et
al
clem
et
al
method
introduc
bia
viral
identif
develop
altern
method
lower
host
genom
materi
clinic
sampl
interest
ethidium
bromid
monoazid
ema
analog
propidium
monoazid
pma
combin
pcr
allow
quantif
live
cell
bacteria
nocker
et
al
nocker
et
al
gatteschi
et
al
codoni
et
al
azidebear
dnarnaintercal
dye
cross
damag
lipid
membran
barrier
dye
bind
coval
crosslink
dnarna
azid
group
convert
highli
reactiv
nitren
radic
upon
exposur
bright
visibl
light
thereaft
easili
inactiv
unbound
inactiv
emapma
remain
free
solut
emapmagener
dnarna
crosslink
strongli
inhibit
reversetranscript
pcr
amplif
emapma
modifi
genom
unmodifi
genom
presumpt
live
bacteria
possess
intact
membran
amplifi
codoni
et
al
interestingli
emapma
treatment
use
distinguish
infecti
noninfecti
virus
hepat
viru
coxsakieviru
echoviru
noroviru
polioviru
suggest
intact
viru
particl
potenti
protect
genet
materi
emapma
chemic
elizaquivel
et
al
theori
emapma
could
use
prevent
host
genom
amplif
pcr
step
conduct
within
pvda
ht
assay
viral
genom
within
intact
virion
inaccess
dye
treatment
amplif
main
object
studi
determin
ema
pma
treatment
increas
efficaci
pvda
ht
detect
virus
clinic
sampl
cell
maintain
describ
previous
use
viru
product
beura
et
al
porcin
reproduct
respiratori
syndrom
viru
prrsv
strain
use
spike
tissu
sera
sampl
iafklop
refer
strain
gagnon
et
al
prrsv
iafklop
strain
stock
obtain
follow
three
cycl
freezethaw
prrsv
infect
cell
afterward
viru
stock
maintain
c
need
infecti
dose
stock
calcul
infect
cell
method
describ
previous
gagnon
et
al
viru
titer
express
tissu
cultur
infecti
dose
per
ml
tcid
ml
lung
blood
sampl
collect
neg
control
prrsv
experiment
infect
piglet
anim
care
done
accord
guidelin
canadian
council
anim
care
protocol
approv
institut
anim
care
committe
protocol
prrsv
strain
involv
infect
prrsv
genbank
access
number
sera
noninfect
infect
piglet
collect
differ
time
postinfect
pi
kept
c
need
viral
load
sampl
determin
specif
prrsv
rtqpcr
assay
previous
describ
bellehumeur
et
al
lung
sampl
collect
necropsi
day
pi
store
c
need
three
infect
lung
sampl
prrsv
titer
tcid
g
select
two
sera
sampl
select
prrsv
posit
clinic
sera
sampl
prrsv
titer
tcid
ml
submit
molecular
diagnost
laboratori
mdl
univers
montreal
select
store
c
need
prrsv
neg
swine
lung
sampl
prrsv
neg
swine
sera
sampl
spike
known
quantiti
prrsv
iafklop
strain
final
concentr
either
tcid
ml
tcid
ml
lung
tissu
sampl
spike
sampl
prrsv
posit
clinic
sampl
mg
tissu
ml
pb
glass
bead
homogen
twice
min
mini
beadbeat
homogen
centrifug
min
rpm
tabl
top
centrifug
kept
c
use
serum
sampl
spike
sampl
prrsv
posit
clinic
sampl
kept
c
thaw
lung
tissu
homogen
serum
sampl
spike
prrsv
clinic
sampl
ultracentrifug
h
rpm
sorval
swing
bucket
rotor
c
ml
sucros
cushion
tne
buffer
mm
trishcl
ph
mm
nacl
mm
edta
viru
pellet
resuspend
tne
buffer
initi
sampl
volum
prior
ultracentrifug
nonultracentrifug
sampl
aliquot
kept
c
durat
ultracentrifug
step
clinic
sampl
lung
tissu
serum
assess
ultracentrifug
ema
pma
biotium
hayward
ca
reconstitut
accord
manufactur
recommend
stock
solut
dilut
rnasefre
water
work
concentr
mm
stock
work
solut
kept
c
use
lung
tissu
homogen
without
ultracentrifug
spike
clinic
sampl
sera
sampl
spike
clinic
sampl
subsequ
treat
ema
final
concentr
pma
final
concentr
equival
volum
water
treat
sampl
incub
dark
min
room
temperatur
min
ice
expos
min
two
w
halogen
light
sourc
distanc
cm
light
sourc
microcentrifug
tube
kept
ice
light
exposur
avoid
excess
heat
follow
treatment
total
dna
rna
extract
use
phenolchloroformisoamyl
alcohol
briefli
l
phenol
solut
ph
ultrapur
tm
buffersatur
phenol
invitrogen
burlington
l
molecular
grade
chloroform
fisher
scientif
ottawa
l
isoamyl
alcohol
fisher
scientif
ad
sampl
sampl
homogen
centrifug
tabletop
microcentrifug
min
rpm
supernat
kept
assess
second
phenolchloroform
step
final
supernat
treat
twice
l
chloroform
total
dna
rna
precipit
ad
l
ethanol
l
sodium
acet
ph
incub
c
overnight
follow
centrifug
min
c
tabletop
microcentrifug
rpm
pellet
repres
total
nucleic
acid
resuspend
l
rnasefre
water
store
freezer
c
use
prrsv
swine
repres
swine
host
genom
dna
quantifi
extract
dnarna
rtqpcr
qpcr
respect
equal
sampl
volum
use
test
ensur
compar
result
prrsv
quantifi
dnarna
extract
test
sampl
use
commerci
ezprrsv
tm
mpx
real
time
rtpcr
kit
tetracor
rockvil
maryland
usa
follow
manufactur
recommend
quantif
done
qpcr
use
ssofast
tm
evagreen
supermix
kit
biorad
hercul
ca
usa
order
evalu
host
genom
spike
clinic
sampl
follow
treatment
sampl
dilut
rnase
free
water
prior
qpcr
test
pcr
amplif
program
quantif
consist
enzym
activ
step
min
c
follow
cycl
denatur
step
c
annealingextens
step
c
use
follow
primer
forward
primer
revers
primer
primer
select
achiev
amplif
effici
data
shown
design
ncbi
genbank
mrna
sequenc
use
webbas
softwar
primerquest
integr
dna
technolog
amplif
step
done
biorad
cfx
apparatu
result
express
ct
valu
follow
treatment
extract
total
nucleic
acid
sampl
use
experi
ie
array
detect
pmaema
treatment
amplifi
use
modifi
random
pcr
protocol
wang
et
al
chen
et
al
randomamplifi
sampl
pvda
test
spike
pg
purifi
plasmid
dna
use
posit
control
local
marker
array
slide
dna
array
dna
array
develop
probe
sequenc
target
prrsv
american
strain
select
prrsv
probe
use
virochip
develop
wang
et
al
deduc
sequenc
align
full
partial
prrsv
genom
sequenc
gather
nation
center
biotechnolog
inform
ncbi
genbank
databas
use
geneiou
pro
softwar
version
biomatt
auckland
new
zealand
http
wwwgeneiouscom
prrsv
homolog
candid
probe
verifi
blastn
select
oligonucleotid
probe
uniqu
target
specif
prrsv
conserv
region
revers
forward
sequenc
conserv
region
select
prrsv
genotyp
strain
two
probe
also
select
target
specif
region
plasmid
dna
array
posit
control
one
probe
select
neg
hybrid
control
total
probe
select
synthes
eurofin
mwg
operon
huntsvil
al
usa
probe
report
gene
express
omnibu
geo
ncbi
databas
access
number
dna
array
spot
done
nation
research
council
canada
previous
describ
vuong
et
al
rt
pcr
randomamplif
step
pcr
product
incub
aminoallyl
aa
dutp
invitrogen
burlington
canada
presenc
klentaq
clontech
previous
describ
wang
et
al
chen
et
al
gener
aadna
purifi
qiaquick
pcr
purif
kit
qiagen
toronto
canada
resuspend
l
rnasefre
water
supplement
l
sodium
bicarbon
thereaft
aadna
incub
presenc
dmsoreconstitut
monoreact
dye
ge
healthcar
life
scienc
pittsburgh
pa
usa
label
dna
purifi
use
qiaquick
pcr
purif
kit
assess
qualiti
use
nanodrop
spectrophotomet
fisher
scientif
toronto
canada
microarray
slide
prehybrid
c
l
dig
easi
hyb
buffer
hoffmannla
roch
limit
mississauga
canada
supplement
l
wv
bovin
serum
albumin
invitrogen
burlington
canada
mm
mm
mm
grace
biolab
hybrislip
tm
coverslip
sigmaaldrich
oakvil
canada
subsequ
cover
slip
remov
dip
glass
slide
ssc
mm
nacl
sodium
citrat
slide
dri
quick
centrifug
total
dna
typic
g
dri
speedvac
fisher
scientif
suspend
l
dig
easi
hyb
buffer
afterward
dna
denatur
min
boil
water
bath
follow
min
incub
ice
sampl
hybrid
overnight
water
bath
c
mm
mm
grace
biolab
hybrislip
tm
sigmaaldrich
final
coverslip
remov
ssc
vv
sodium
dodecyl
sulfat
sd
slide
wash
three
time
ssc
vv
sd
ssc
min
per
wash
hybrid
array
imag
use
fluoresc
scanner
scanarray
perkin
elmer
mississauga
canada
scanarray
softwar
version
fluoresc
spot
intens
scan
laser
fluoresc
intens
quantifi
use
scanarray
softwar
version
dna
array
fluoresc
intens
result
analyz
microsoft
excel
tm
intens
spot
probe
compar
averag
intens
two
neg
control
spot
probe
consid
posit
averag
signaltonois
fluoresc
ratio
duplic
spot
fig
prrsv
host
genom
detect
spike
tissu
follow
ema
pma
treatment
use
qpcr
effect
ema
pma
treatment
without
ultracentrifug
prrsv
quantif
b
host
genom
dna
lung
tissu
homogen
spike
prrsv
serum
spike
prrsv
result
express
ct
obtain
two
seven
independ
experi
result
independ
experi
trial
illustr
supplement
fig
sampl
repres
type
tissu
spike
prrsv
number
bracket
repres
prrsv
concentr
spike
sampl
express
open
bar
repres
result
obtain
sampl
process
without
ultracentrifug
step
fill
bar
repres
result
obtain
sampl
treat
ultracentrifug
step
ct
valu
dash
line
repres
limit
detect
qpcr
test
label
two
set
data
differ
letter
indic
two
set
data
statist
differ
p
set
data
use
letter
superscript
number
must
compar
togeth
random
amplifi
sampl
endrepair
atail
use
kapa
high
throughput
librari
prepar
kit
spri
solut
standard
pcr
librari
amplificationillumina
seri
kapa
biosystem
wilmington
usa
illumina
truseq
ht
dual
index
adapt
illumina
sandiego
ca
usa
ligat
amplifi
sampl
librari
amplifi
kapa
kit
final
cleanup
qualiti
librari
assess
high
sensit
dna
chip
agil
santa
clara
ca
usa
use
bioanalyz
agil
equal
amount
librari
pool
sequenc
illumina
miseq
pairedend
read
dualindex
plateform
danalys
de
linstitut
de
biologi
et
de
de
laval
quebec
qc
canada
raw
sequenc
read
trim
random
amplif
primer
map
su
scrofa
genom
prrsv
iafklop
viral
genom
sequenc
use
gsmapper
applic
newbler
parametr
oneway
anova
model
follow
tukey
multipl
comparison
test
graphpad
prism
version
softwar
use
determin
statist
signific
differ
exist
quantif
target
gene
prrsv
treat
untreat
sampl
evalu
qpcr
rtqpcr
nonparametr
oneway
anova
model
follow
dunn
multipl
comparison
test
graphpad
prism
softwar
use
determin
statist
signific
differ
exist
mean
rel
fluoresc
intens
prrsv
detect
probe
dna
array
treat
untreat
sampl
ratio
posit
prrsv
read
compar
total
amount
read
follow
treatment
analyz
mix
linear
model
trial
number
random
factor
treatment
fix
factor
follow
tukey
multipl
comparison
test
sa
version
softwar
cari
nc
usa
ht
result
also
evalu
individu
use
chisquar
test
order
determin
odd
obtain
posit
prrsv
read
differ
follow
select
treatment
compar
total
amount
read
relat
prrsv
graphpad
prism
softwar
final
spearman
nonparametr
correl
also
use
evalu
relat
presenc
dna
contamin
read
posit
prrsv
read
well
ratio
prrsv
read
prrsv
percent
coverag
ht
result
sa
version
softwar
differ
consid
statist
signific
p
except
chisquar
test
result
p
p
consid
signific
order
select
effect
concentr
ema
pma
treatment
preliminari
experi
done
prrsv
spike
lung
sampl
tcid
ml
data
shown
final
ema
pma
concentr
select
realiz
subsequ
experi
use
concentr
effect
ema
pma
treatment
viru
genom
presenc
host
genom
dna
evalu
tissu
sampl
spike
known
quantiti
prrsv
tcid
ml
tcid
ml
also
serum
sampl
spike
prrsv
quantiti
result
lung
homogen
spike
concentr
prrsv
indic
ema
pma
treatment
significantli
lower
prrsv
detect
compar
nontreat
sampl
fig
p
p
respect
howev
prrsv
detect
neg
affect
follow
ema
treatment
fig
p
indic
pma
treatment
less
neg
impact
rtqpcr
prrsv
detect
observ
preliminari
experi
ultracentrifug
signific
posit
impact
prrsv
detect
lung
tissu
homogen
spike
either
concentr
prrsv
follow
ema
treatment
fig
p
lung
tissu
homogen
spike
highest
concentr
prrsv
ultracentrifug
also
increas
significantli
prrsv
detect
follow
treatment
follow
pma
treatment
fig
p
p
respect
spike
serum
sampl
ema
treatment
significantli
decreas
prrsv
detect
fig
p
ultracentrifug
significantli
improv
prrsv
detect
nontreat
spike
sera
sampl
fig
p
significantli
decreas
prrsv
rtqpcr
detect
ema
treat
spike
sera
sampl
fig
p
ema
pma
treatment
combin
ultracentrifug
equal
effici
lower
amplif
prrsv
spike
lung
tissu
homogen
fig
p
ultracentrifug
nontreat
spike
lung
tissu
sampl
also
slightli
lower
amount
fig
p
spike
sera
sampl
alreadi
limit
detect
untreat
sampl
indic
hgcont
much
lower
sera
compar
lung
tissu
homogen
fig
dna
array
sensit
ema
pma
treat
prrsv
spike
tissu
nucleic
acid
extract
random
amplif
dna
label
done
spike
sampl
fluoresc
prrsv
probe
measur
follow
hybrid
label
sampl
dna
array
compar
neg
probe
fluoresc
intens
see
access
number
geo
ncbi
databas
raw
data
surprisingli
probe
signal
intens
posit
vari
experi
lung
sampl
spike
prrsv
tcid
ml
low
number
slightli
posit
probe
probe
rel
signal
intens
detect
untreat
sampl
fig
interestingli
multipl
probe
rel
high
fluoresc
intens
detect
follow
pma
treatment
combin
ultracentrifug
associ
significantli
higher
number
posit
probe
compar
untreat
sampl
ultracentrifug
pma
treat
sampl
without
ultracentrifug
fig
p
contrast
fluoresc
intens
detect
posit
probe
ematr
lung
homogen
spike
prrsv
tcid
ml
significantli
lower
experiment
group
indic
lower
chanc
detect
posit
probe
follow
treatment
ema
p
fig
lung
sampl
spike
higher
concentr
prrsv
tcid
ml
small
number
low
intens
posit
probe
fluoresc
rel
signal
posit
probe
fluoresc
rel
signal
detect
untreat
sampl
fig
signific
increas
number
high
intens
posit
probe
fluoresc
rel
signal
found
sampl
treat
pma
without
ultracentrifug
compar
untreat
sampl
without
ultracentrifug
fig
p
surprisingli
posit
probe
found
sampl
treat
ultracentrifug
ema
similar
untreat
sampl
howev
number
intens
probe
sampl
treat
ema
without
ultracentrifug
significantli
higher
compar
untreat
sampl
without
ultracentrifug
p
spike
sera
sampl
interest
observ
experiment
group
larg
number
probe
high
intens
fluoresc
signal
prrsv
includ
untreat
sampl
fig
indic
overal
treatment
ultracentrifug
versu
pmaema
improv
dna
array
sensit
use
sera
sampl
interestingli
pma
treatment
compar
untreat
sera
reduc
pvda
sensit
even
high
number
high
intens
posit
probe
observ
pma
treat
sera
fig
p
dna
sequenc
obtain
sequenc
experi
compar
swine
mitochondri
genbank
access
number
nc
chromosom
genom
dna
sequenc
genbank
access
number
nc
nc
well
full
genet
sequenc
prrsv
strain
use
studi
ht
read
associ
prrsv
sequenc
also
consid
evalu
viru
coverag
obtain
follow
treatment
combin
two
three
experi
pma
ema
treat
prrsv
spike
lung
tissu
tcid
ml
signific
increas
number
prrsv
read
compar
untreat
sampl
reveal
chisquar
analysi
fig
p
strong
correl
found
prrsv
percent
coverag
higher
number
read
follow
treatment
r
p
indic
increas
prrsv
coverag
relat
augment
prrsv
read
howev
b
c
fig
prrsv
detect
spike
sampl
dna
array
follow
ema
pma
treatment
dna
array
probe
rel
intens
lung
tissu
homogen
spike
prrsv
b
lung
tissu
homogen
spike
prrsv
c
serum
sampl
spike
prrsv
dot
rel
fluoresc
intens
mean
valu
two
ident
probe
gather
two
seven
independ
experi
experi
consist
duplic
prrsv
specif
probe
calcul
follow
pfl
bfl
bfl
pfl
repres
prrsv
probe
fluoresc
intens
bfl
repres
basal
fluoresc
level
neg
control
probe
fluoresc
result
independ
experi
trial
illustr
supplement
fig
line
repres
fluoresc
mean
valu
probe
open
dot
circl
repres
result
obtain
sampl
process
without
ultracentrifug
step
fill
dot
circl
repres
result
obtain
sampl
treat
ultracentrifug
step
label
two
set
data
differ
letter
indic
two
set
data
statist
differ
p
probe
rel
intens
dash
line
repres
lowest
limit
dna
array
posit
result
open
bar
repres
result
obtain
sampl
process
without
ultracentrifug
step
fill
bar
repres
result
obtain
sampl
treat
ultracentrifug
step
result
experi
express
separ
graphic
label
two
set
data
differ
letter
indic
two
set
data
statist
differ
p
set
data
use
letter
superscript
number
must
compar
togeth
overal
pvalu
shown
box
repres
statist
analysi
treatment
effect
take
account
experiment
group
three
ht
experi
combin
togeth
statist
analys
signific
differ
obtain
amount
prrsv
specif
read
total
amount
read
fig
p
prrsv
percentag
coverag
fig
p
noteworthi
experi
show
improv
amount
prrsv
read
associ
higher
level
hgcont
reveal
fig
fact
strong
neg
correl
found
ratio
prrsv
read
number
prrsv
readstot
number
read
ratio
host
genom
read
number
genom
readstot
number
read
r
p
three
experi
reason
experi
indic
low
effect
treatment
percentag
host
genom
dna
possibl
transcript
current
unknown
might
caus
higher
rate
host
genom
releas
tissu
prepar
tissu
homogen
spike
higher
amount
prrsv
tcid
ml
although
statist
signific
statist
analys
reveal
tendenc
increas
ratio
prrsv
read
two
ht
experi
taken
account
fig
p
moreov
signific
variat
found
prrsv
coverag
sampl
fig
p
signific
increas
prrsv
coverag
pma
treat
sampl
without
ultracentrifug
observ
fig
p
ultracentrifug
sampl
contain
higher
amount
prrsv
improv
either
prrsv
number
read
coverag
fig
e
prrsv
spike
sera
import
increas
ratio
prrsv
read
coverag
untreat
sampl
compar
result
obtain
lung
homogen
fig
accord
lower
amount
host
genom
dna
detect
sera
untreat
sampl
fig
accord
chisquar
analysi
slight
increas
prrsv
ratio
read
observ
follow
pma
ema
treatment
howev
ultracentrifug
lower
ratio
prrsv
read
combin
ema
treatment
fig
associ
lower
prrsv
coverag
fig
highthroughput
sequenc
effici
ema
pma
treat
prrsv
posit
clinic
sampl
order
confirm
effect
ema
pma
treatment
increas
sensit
pvda
ht
detect
virus
two
set
data
group
data
label
asterisk
indic
two
set
data
group
statist
differ
p
label
two
set
data
differ
letter
indic
two
set
data
statist
differ
p
set
data
use
letter
superscript
number
compar
togeth
techniqu
evalu
differ
prrsv
posit
clinic
sampl
gather
prrsv
experiment
infect
piglet
clinic
sampl
submit
mdl
clinic
sampl
ultracentrifug
treat
pma
untreat
pma
select
overal
previou
find
indic
pma
treatment
effici
ema
regard
prrsv
rtqpcr
pvda
ht
detect
prrsv
amplifi
host
genom
dna
copi
number
significantli
reduc
pma
treat
lung
tissu
fig
b
p
import
prrsv
decreas
pma
treat
sampl
probabl
caus
presenc
damag
virion
andor
nonencapsid
viral
genom
within
clinic
sampl
prrsv
undetect
untreat
sampl
dna
array
fig
interestingli
sever
prrsv
probe
found
posit
lung
pma
treat
sampl
fig
p
howev
prrsv
detect
dna
array
lung
prrsv
probe
found
posit
lung
follow
pma
treatment
fig
ht
result
three
clinic
case
taken
account
togeth
result
reveal
pma
tend
increas
number
read
obtain
lung
tissu
compar
untreat
sampl
fig
p
nonetheless
pma
treatment
significantli
improv
percentag
prrsv
ht
read
two
three
clinic
case
test
fig
p
although
experi
show
import
increas
prrsv
genom
coverag
overal
signific
differ
detect
fig
p
increas
prrsv
coverag
detect
lung
fig
although
lung
show
increas
percentag
prrsv
read
import
increas
prrsv
two
set
data
group
data
label
asterisk
indic
two
set
data
group
statist
differ
p
p
label
two
set
data
differ
letter
indic
two
set
data
statist
differ
p
set
data
use
letter
superscript
number
compar
togeth
coverag
detect
howev
higher
host
genom
dna
content
observ
sampl
suggest
lower
ct
valu
detect
treat
untreat
sampl
fig
higher
genom
percentag
read
fig
compar
lung
pma
treatment
clinic
sera
signific
effect
amplifi
prrsv
fig
host
genom
dna
level
fig
ct
valu
agreement
spike
sera
sampl
prrsv
strongli
detect
experiment
condit
test
clinic
sera
sampl
pvda
ht
fig
e
howev
number
prrsv
posit
probe
significantli
lower
pma
treat
sampl
sera
sampl
fig
p
ht
result
reveal
pma
treatment
also
lower
ratio
prrsv
read
one
two
case
fig
p
prrsv
coverag
high
case
except
serum
treat
pma
prrsv
percent
coverag
slightli
higher
although
gener
prefer
direct
viru
isol
identif
clinic
sampl
alway
possibl
sometim
lead
misidentif
etiolog
agent
consequ
direct
identif
within
clinic
sampl
use
newli
avail
genom
technolog
desir
past
decad
pvda
ht
technolog
led
discoveri
new
virus
mishra
et
al
yozwiak
et
al
nakamura
et
al
blomstrom
et
al
mihindukulasuriya
et
al
victoria
et
al
hang
et
al
rosseel
et
al
howev
sensit
technolog
suffer
excess
amount
contamin
host
dna
rna
methodolog
decreas
mask
effect
contamin
viral
detect
import
new
approach
lower
host
genom
dna
within
clinic
sampl
present
report
result
support
increas
sensit
pvda
ht
lung
tissu
sampl
treat
pma
lesser
extent
ema
treatment
done
standalon
treatment
combin
treatment
like
ultracentrifug
surprisingli
ad
ultracentrifug
step
ema
pma
treatment
sometim
lower
sensit
pvda
ht
probabl
caus
physic
degrad
viral
particl
ultracentrifug
make
particl
sensit
ema
pma
treatment
interestingli
result
indic
higher
sensit
pvda
ht
sera
sampl
compar
tissu
homogen
may
explain
two
phenomena
firstli
lower
concentr
hgcont
sera
sampl
compar
tissu
homogen
demonstr
dna
measur
untreat
sera
sampl
tissu
homogen
secondli
random
amplif
method
use
increas
amount
dna
ht
pvda
techniqu
amplifi
nucleic
dna
rna
sequenc
found
sampl
includ
hgcont
thu
sensit
pvda
ht
highli
affect
ratio
viral
genet
materi
interest
total
amount
hgcont
found
sampl
indic
initi
amount
hgcont
clinic
sampl
deep
impact
pvda
ht
sensit
identif
virus
variat
hgcont
content
within
nucleic
acid
extract
clinic
sampl
may
explain
high
standard
deviat
obtain
within
result
pvda
ht
lung
tissu
homogen
spike
lowest
prrsv
concentr
variat
explain
multipl
factor
like
extract
method
tissu
qualiti
homogen
process
also
viru
integr
clinic
sampl
taken
account
avoid
viru
particl
degrad
tissu
manipul
storag
homogen
sensit
viral
particl
ema
pma
treatment
especi
true
clinic
sampl
viru
type
integr
tissu
dead
anim
sampl
conserv
room
temperatur
etc
amount
hgcont
presenc
pcr
inhibitor
critic
impact
pvda
ht
sensit
addit
effici
random
amplif
process
could
affect
viral
genom
sequenc
secondari
structur
make
viral
genom
less
compat
use
random
amplif
prior
ht
pvda
codoni
et
al
import
note
work
util
uniqu
viru
take
account
effici
ema
pma
treatment
type
virus
howev
outer
structur
virion
sever
virus
protect
viral
genet
materi
pma
treatment
elizaquivel
et
al
suggest
treatment
reduc
influenc
hgcont
use
clinic
sampl
viru
type
multipl
report
reveal
differenti
pvda
ht
sensit
viral
detect
identif
clinic
sampl
follow
use
differ
treatment
combin
includ
ultracentrifug
nucleas
treatment
mishra
et
al
djikeng
et
al
lowest
viral
load
spike
serum
sampl
shown
nicholson
collabor
determin
limit
pvda
detect
prrsv
spike
serum
sampl
subject
nucleas
treatment
tcid
ml
nicholson
et
al
similar
result
obtain
present
studi
lower
viru
concentr
tcid
ml
previou
studi
report
ratio
viral
sequenc
read
total
number
read
rang
nonnucleas
treat
serum
nasopharyng
aspir
yozwiak
et
al
nakamura
et
al
howev
mishra
collabor
show
ratio
viral
readstot
number
read
ht
muscl
tissu
sampl
mishra
et
al
studi
rrna
deplet
dnase
treatment
done
follow
rna
extract
order
lower
hgcont
clinic
sampl
mishra
et
al
result
accord
work
sinc
percentag
prrsv
specif
read
rang
spike
untreat
sampl
ema
pmatreat
spike
sampl
contrast
djikeng
collabor
report
much
higher
ratio
host
genom
content
isol
viru
rang
djikeng
et
al
nakamura
collabor
report
higher
genom
content
rang
nakamura
et
al
variat
host
genom
dna
content
studi
probabl
explain
differ
purif
treatment
method
use
viru
like
use
gradient
densiti
centrifug
obtain
highli
purifi
virus
lower
hgcont
djikeng
et
al
ratio
host
genom
dna
content
report
studi
vari
untreat
sampl
ema
pmatreat
sampl
repres
improv
result
report
nakamura
collabor
purif
method
use
less
ratio
hgcont
report
djikeng
collabor
howev
last
case
virus
isol
cell
cultur
virion
subsequ
purifi
thu
result
indic
ema
pma
treatment
improv
sensit
pvda
ht
detect
virus
clinic
sampl
contamin
hgcont
furthermor
emapma
treatment
faster
easier
perform
nucleas
treatment
firstli
requir
shorter
incub
time
compar
nucleas
treatment
would
result
faster
process
clinic
sampl
diagnost
laboratori
increas
robust
method
exert
less
stress
temperatur
sensit
viral
particl
secondli
ema
pma
easi
inactiv
light
exposur
subsequ
leav
emapma
molecul
unabl
destroy
newli
expos
viral
genom
materi
follow
nucleic
acid
extract
unlik
case
residu
nucleas
may
still
present
nucleic
acid
purif
step
especi
true
rnase
dnase
treatment
use
presenc
rna
dna
virus
respect
pmaema
treatment
effect
tissu
sampl
compar
sera
sampl
presum
due
lower
hgcont
latter
pma
effect
ema
improv
ht
pvda
sensit
viral
detect
clinic
sampl
would
explain
fact
ema
leak
phospholipid
bilay
membran
nocker
et
al
moreov
ultracentrifug
appear
lower
sensit
ht
pvda
follow
treatment
possibl
direct
physic
degrad
viral
particl
conclus
pretreat
clinic
sampl
ema
especi
pma
repres
interest
novel
approach
improv
pvda
ht
sensit
identif
virus
clinic
sampl
